Since the treatment of AD and related dementias represents an increasing problem in global health and is becoming a more and more economic burden, especially on a global level, the development and optimization of new cholinesterase inhibitors with improved pharmacological properties than those in clinical use is an on-going hot research topic. This evidence concerns the gene BCHE and Alzheimer disease.